Drug Trial Radar · NCT05683717
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
Last checked: Nov 19, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
37
Planned (sponsor's estimate)
Start
Mar 30, 2023
Primary completion
Oct 31, 2026
Study completion Oct 30, 2028
Sponsor
- Lead sponsor
- TransThera Sciences (Nanjing), Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.
Conditions
- B-Cell Malignancies
Interventions
TT-01488 TabletsDrug
TT-01488 tablet will be administered orally once daily per protocol defined schedule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity (DLT) of TT-01488Time frame: Up to 28 days after first dose
- Dose recommend for dose expansion (DRDE)Time frame: 3 years
- Maximum Tolerated Dose (MTD), if reached, of TT-01488Time frame: Up to 28 days after first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.